WHO ICTRP trial
Clinical investigation on the efficacy and safety of Chimeric Antigen Receptor…
ChiCTR-INh-16008198 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-INh-16008198 |
|---|---|
| Public title | Clinical investigation on the efficacy and safety of Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in relapsed and refractory multiply myeloma |
| Scientific title | Clinical investigation of Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in relapsed and refractory multiply myeloma |
| Primary sponsor | Department of Hematology, Changzheng Hospital, The Second Military Medical University. |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | New Treatment Measure Clinical Study |
| Countries | China |
| Conditions | Multiple Myeloma |
| Interventions | Treatment group:Chimeric Antigen Receptor T-Cell Immunotherapy |
| Registration date | Mar 31, 2016 |
| Target size | Treatment group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: